Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: The indian perspective

被引：7

作者：

Soni A. ^{[1
]}

Garg S. ^{[1
]}

Bangar R. ^{[1
]}

机构：

[1] Department of Obstetrics and Gynecology, Dr. LH Hiranandani Hospital, Powai, Mumbai 400076 Maharashtra, Hillside Avenue, Hiranandani Gardens

来源：

The Journal of Obstetrics and Gynecology of India | 2013年 / 63卷 / 5期

关键词：

Combined vaginal contraceptive ring; Cycle control; Efficacy;

D O I：

10.1007/s13224-013-0391-5

中图分类号：

学科分类号：

摘要：

Objective: To assess the contraceptive efficacy, user acceptability, cycle control, and tolerability of a combined contraceptive vaginal ring for up to 13 cycles. Materials and Methods: Healthy women coming to the OPD for contraceptive advice were enrolled in this one-year study. Each ring was used for three weeks followed by a one-week ring-free period. Results: A total of 184 women started treatment forming the intent to treat population. Subjects were followed for 13 cycles. Compliance was good with 99 % of cycles in full compliance with specified criteria. In the intent to treat population, no pregnancies occurred giving a Pearl Index of 0. The mean incidence of withdrawal bleeding was 99 % in all cycles. There was 0.16 % incidence of intermenstrual bleeding and 2 % incidence of early withdrawal bleeding. The ring was well tolerated with a low incidence of adverse events. Conclusion: The ring is an effective contraceptive that is convenient, well tolerated with excellent cycle control, and highly acceptable to users. © 2013 Federation of Obstetric & Gynecological Societies of India.

引用

页码：337 / 341

页数：4

共 14 条

[1]

Fotherby K., Caldwell A.D., New progestogens in oral contraception, Contraception, 49, pp. 1-32, (1994)

[2]

Rosenberg M.J., Waugh M.S., Meehan T.E., Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation, Contraception, 51, pp. 283-288, (1995)

[3]

Zibners A., Cromer B.A., Hayes J., Comparison of continuation rates for hormonal contraception among adolescents, J Pediatr Adolesc Gynecol, 12, pp. 90-94, (1999)

[4]

Rosenberg M., Waugh M.S., Causes and consequences of oral contraceptive noncompliance, Am J Obstet Gynecol, 180, pp. 276-279, (1999)

[5]

Rosenberg M.J., Waugh M.S., Burnhill M.S., Compliance, counseling and satisfaction with oral contraceptives: A prospective evaluation, Fam Plann Perspect, 30, pp. 89-92, (1998)

[6]

Weisberg E., Fraser I.S., Lacarra M., Et al., Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring, Contraception, 59, pp. 311-318, (1999)

[7]

Roumen F., Apter D., Mulders T.M.T., Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol, Hum Reprod, 16, pp. 469-475, (2001)

[8]

Timmer C.J., Mulders T.M.T., Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring, Clin Pharmacokinet, 39, pp. 233-242, (2000)

[9]

Mudlers T.M.T., Dieben T.O.M., Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition, Fertil Steril, 75, pp. 865-870, (2001)

[10]

Dieben T.O.M., Jme Roumen F., Apter D., Efficacy, cycle control, user acceptability of a novel contraceptive ring, Obstet Gynecol., 100, pp. 585-593, (2002)

← 1 2 →